In many cases of acute myeloid leukemia (AML), genetic abnormalities occur in transcriptional control elements, leading to uncontrolled proliferation and a block in differentiation. Chromosomal translocations have been shown to create either fusion gene products, such as AML1/ETO, or dysregulation, as in the case of the retinoic acid in acute promyelocytic leukemia (PML). However, in a significant number of patients, no chromosomal translocation is identified. In these cases, mutations or aberrant post-transcriptional events in regulatory proteins have been postulated.
The most prevalent transcriptional regulatory element in which mutations have been identified in AML is the CCAATenhancer binding protein alpha (C/EBP-␣).
1 A significant percentage of AML patients without chromosomal translocations have demonstrated abnormalities in C/EBP-␣ protein or function, suggesting that loss of transcriptional control is a common mechanism of leukemogenesis. Even in the setting of other proleukemogenic genetic abnormalities, such as the (8;21) translocation, C/EBP-␣ has been demonstrated to be aberrantly regulated, in this case by downregulation of expression. 2 The C/EBP-␣ protein has been demonstrated to play a role in normal granulocytic differentiation. C/EBP-␣ often binds to a sequence that looks like, but is not always identical to, CCAAT. C/EBP-␣ is expressed in liver and adipose tissue and plays a critical role in myeloid development. When C/EBP-␣ is transfected into early myeloid cells, the cells undergo granulocytic, but not myelocytic, differentiation. Since this protein is both necessary and sufficient for development of the granulocytic lineage, one would predict that its disruption would be similar to the block in differentiation found in leukemia. In C/EBP-␣ knockout mice, all the cell lineages are normal except that the granulocytic cells and the granulocytic blasts undergo early maturation arrest.
Mutations in C/EBP-␣ have been demonstrated in a subset of patients with AML. In our study, 10 of 150 AML patients with normal karyotypes had mutations. 3 All were of the M1 and M2 FAB subtype. Interestingly, there were no mutations in M2 patients who had the AML1/ETO translocation, perhaps due to the fact that one mutational event driving proliferation is sufficient to initiate leukemogenesis. When the mutations in C/EBP-␣ were sequenced, it was demonstrated that most were heterozygous, suggesting that they are dominant negatives. As seen in gel shift assays, most of these mutants do not bind their target gene and are therefore unable to function as transcriptional regulators. The mutant proteins were able to compete with and block binding of the wild-type. 4 In the case of PML, the major focus has been on the effects of the retinoic acid receptor (RAR) and retinoid-responsive genes on myeloid differentiation. Since mutations of C/EBP-␣ were not found in patients with PML that demonstrated the t(15;17) translocation, nor was C/EBP-␣ downregulated, we hypothesized that the PML/RAR fusion protein in these cells may interfere with the function, but not expression, of C/EBP-␣. To demonstrate this, we performed colocalization studies. Immunostaining for C/EBP-␣ protein in normal marrow blasts demonstrated diffuse nuclear staining, suggesting random distribution of C/EBP-␣. In patients with PML, the immunostaining for C/EBP-␣ clustered in nuclear bodies and colocalized with PML-RAR. After therapy with all-trans retinoic acid (ATRA), there was a restoration of the normal pattern of C/EBP-␣ binding and no colocalization. These results suggested possibly a physical interaction between the PML/RAR fusion protein and C/EBP-␣. To further address this, we performed coimmunoprecipitation studies, which demonstrated that C/EBP-␣ interacts very strongly with itself and forms a homodimer, a bZIP protein. This homodimer interacted strongly with the PML/RAR fusion protein, but weakly with either PML or with the retinoic acid receptor. 5 We also determined that mutants of PML-RAR, which are unable to interact with the corepressors, were capable of binding to C/EBP-␣. This suggests that binding of corepressors has little effect on the function of PML-RAR to block myeloid differentiation. One possibility to explain the effect of dimerization of C/EBP-␣ with PML-RAR on C/EBP-␣ activity is that the interaction may serve to inhibit C/EBP-␣ binding to transcriptional elements. This was confirmed in gel shift assays in which inducible PML-RAR was shown to inhibit C/EBP-␣ binding. Retinoic acid was subsequently shown to reverse this interaction and to restore C/EBP-␣ binding. If we believe that C/EBP-␣ plays a major role in granulocytic differentiation, then interaction with the fusion protein in PML-RAR would block binding of C/EBP-␣ to target genes and therefore block differentiation. Possible mechanisms for this include blocking the ability of retinoic acid receptor to transactivate its target genes.
In summary, the C/EBP-␣ pathway is important in at least three different major subtypes of AML. In patients with the AML M1 or M2 subtypes, we observed that dominant negative mutations occur in this gene, leading to loss of function. In promyelocytic leukemias, there was interaction with the PML/RAR fusion protein, leading to inhibition of DNA binding. In the setting of the t(8;21) translocation, the AML1/ETO fusion protein has been demonstrated to inhibit C/EBP-␣ function and downregulate its expression. 6 In our limited screen of other leukemias, no mutations or abnormalities in regulation have been noted. However, it is certainly possible that some of these other fusion proteins could affect C/EBP-␣ function, similar to PML-RAR.
These results reiterate the pivotal role of transcriptional dysregulation in the pathogenesis of acute myeloid leukemia.
Recent therapeutic interventions have attempted to directly modulate the expression of aberrant fusion proteins, such as with the use of ATRA in PML and BCR/ABL tyrosine kinase inhibitors in chronic myeloid leukemia. If C/EBP-␣ in fact may represent a common denominator among patients with AML, with and without chromosomal translocations, then approaches directed at this pathway may represent rational therapeutic strategies in the future. Elucidation of the basic pathways underlying myeloid differentiation, such as the C/EBP-␣, and understanding how these pathways are disrupted in AML, will help define future therapeutic approaches to AML.
